1st In Media PYMNTS.com, 111 Devonshire St, Boston, MA 02109, US

Inotek Pharmaceuticals is a privately held biotechnology company based in Lexington, MA, focused on the discovery and development of innovative drugs to treat serious eye diseases such as glaucoma, ocular hypertension, age-related macular degeneration, and retinal neuropathies. Their lead program, trabodenoson INO-8875, is a highly selective adenosine mimetic that targets the A1 sub-receptor, offering a novel mechanism of action for reducing intraocular pressure associated with glaucoma and ocular hypertension. With a deep pipeline of drug candidates, Inotek Pharmaceuticals aims to address inflammation, ischemia-reperfusion injury, and oxidative stress, which are key targets for eye disease treatments. Their experienced management team and successful track record in advancing clinical programs towards commercialization position the company to benefit patients and physicians managing ocular diseases.Generated from the website

Ufcw Local 8D

Marathon Investment Management

Patriot National Insurance Group

Glenn Alberich Law Offices